CA2729834A1 - Formulations for treating eye disorders - Google Patents

Formulations for treating eye disorders Download PDF

Info

Publication number
CA2729834A1
CA2729834A1 CA2729834A CA2729834A CA2729834A1 CA 2729834 A1 CA2729834 A1 CA 2729834A1 CA 2729834 A CA2729834 A CA 2729834A CA 2729834 A CA2729834 A CA 2729834A CA 2729834 A1 CA2729834 A1 CA 2729834A1
Authority
CA
Canada
Prior art keywords
ocular
solution
nampa
eye
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2729834A
Other languages
English (en)
French (fr)
Inventor
Edward Chong
Clive Burge
Lee Mizzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspreva International Ltd
Original Assignee
Aspreva International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspreva International Ltd filed Critical Aspreva International Ltd
Publication of CA2729834A1 publication Critical patent/CA2729834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2729834A 2008-07-09 2009-07-09 Formulations for treating eye disorders Abandoned CA2729834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7941308P 2008-07-09 2008-07-09
US61/079,413 2008-07-09
PCT/IB2009/006683 WO2010004435A2 (en) 2008-07-09 2009-07-09 Formulations for treating eye disorders

Publications (1)

Publication Number Publication Date
CA2729834A1 true CA2729834A1 (en) 2010-01-14

Family

ID=41505728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2729834A Abandoned CA2729834A1 (en) 2008-07-09 2009-07-09 Formulations for treating eye disorders

Country Status (6)

Country Link
US (1) US20100010082A1 (cg-RX-API-DMAC7.html)
EP (1) EP2310008A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011527339A (cg-RX-API-DMAC7.html)
CN (1) CN102099029A (cg-RX-API-DMAC7.html)
CA (1) CA2729834A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010004435A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20100331430A1 (en) * 2009-06-30 2010-12-30 Allergan, Inc. Pharmaceutical compositions containing propionic preservative components
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
US8829053B2 (en) * 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
KR102433489B1 (ko) * 2013-03-14 2022-08-17 팬옵티카, 인크. 눈의 후안부로의 약물 전달을 위한 안구용 제제
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
CA2947619A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR20170043655A (ko) 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
US20230158045A1 (en) * 2017-09-25 2023-05-25 Surface Ophthalmics, Inc. Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20210177751A1 (en) * 2017-12-08 2021-06-17 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
JP2022516099A (ja) * 2018-12-27 2022-02-24 サーフィス オフサルミクス,インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
WO2021124301A1 (en) * 2019-12-20 2021-06-24 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法
CN116973187A (zh) * 2023-07-10 2023-10-31 益诺思生物技术南通有限公司 一种眼球组织制片方法及眼球组织切片

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
WO1989001772A1 (en) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
JPH0930966A (ja) * 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium

Also Published As

Publication number Publication date
WO2010004435A2 (en) 2010-01-14
EP2310008A4 (en) 2014-03-05
EP2310008A2 (en) 2011-04-20
CN102099029A (zh) 2011-06-15
WO2010004435A9 (en) 2010-08-26
WO2010004435A3 (en) 2010-06-24
US20100010082A1 (en) 2010-01-14
JP2011527339A (ja) 2011-10-27

Similar Documents

Publication Publication Date Title
US20100010082A1 (en) Formulations for treating eye disorders
US20260115172A1 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
US6579901B2 (en) Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
US9937225B2 (en) Topical formulations and uses thereof
Pisella et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits
RU2582609C2 (ru) Соединения для лечения/профилактики воспалительных глазных заболеваний
Okabe et al. Effect of benzalkonium chloride on transscleral drug delivery
US20180092927A1 (en) Topical formulations and uses thereof
KR101778004B1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
CN114126580A (zh) 用于治疗眼部过敏的眼用组合物
CN118403054A (zh) 用于控制和/或降低近视发展的药物组合物
US20140322193A1 (en) Therapies for Disorders of the Cornea and Conjunctiva
Zhou et al. Subconjunctival injection of microcrystalline prodrug of dexamethasone for long-acting anti-inflammation after phacoemulsification surgery
JP4475802B2 (ja) 緑内障の局所治療用フルナリジンの使用法
CN116459251B (zh) 一种含西维美林的眼用制剂及其制备方法和应用
CN118873493A (zh) 一种他克莫司眼用纳米乳的制备方法及用途
CN114040783A (zh) 可用于治疗干眼症的组合物和方法
JP2007537282A (ja) ドライアイ障害およびブドウ膜炎を処置するための方法
HK40070050A (en) Compositions and methods useable for treatment of dry eye

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140625

FZDE Discontinued

Effective date: 20160711